Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a ...

Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...